As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals ...

D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...